COPD气道上皮转录组分析:气道嗜酸粒细胞增多与2型炎症及激素反应相关
该研究基于DISARM随机对照试验的事后分析,对58例COPD患者的气道上皮刷检样本进行RNA测序,比较伴或不伴气道嗜酸粒细胞增多(BAL中嗜酸粒细胞>1%总白细胞)患者的基因表达。结果显示38%患者存在气道嗜酸粒细胞增多,该组基线气道上皮2型炎症、IL-13及肥大细胞基因特征表达更高,且12周ICS治疗后上述基因特征表达显著降低,而不伴气道嗜酸粒细胞增多组变化不显著。
要点
- COPD患者中38%存在气道嗜酸粒细胞增多(BAL嗜酸粒细胞>1%总白细胞)。
- 气道嗜酸粒细胞增多组气道上皮2型炎症、IL-13及肥大细胞基因特征表达更高。
- ICS治疗12周可降低气道嗜酸粒细胞增多组2型炎症和肥大细胞基因特征表达。
核心结论
- 气道嗜酸粒细胞增多标识了一部分COPD患者,其气道上皮2型炎症表达增高并对ICS治疗有反应。
研究设计与样本
- DISARM随机对照试验的事后分析,纳入58例COPD患者,对气道上皮刷检样本行RNA测序分析基线及12周ICS治疗后的基因表达。
主要发现
- 58例COPD患者中38%存在基线气道嗜酸粒细胞增多。
- 气道嗜酸粒细胞增多组气流阻塞更严重且影像学肺气肿更明显。
- 气道嗜酸粒细胞增多组基线气道上皮2型炎症、IL-13及肥大细胞活化表达更高,而1型和17型炎症表达与无气道嗜酸粒细胞增多组相似。
- 气道嗜酸粒细胞增多组2型免疫反应和哮喘相关经典通路上调。
- 12周ICS治疗降低气道嗜酸粒细胞增多组气道上皮2型炎症和肥大细胞基因特征表达,而无气道嗜酸粒细胞增多组变化不显著。
关键数值与推荐
- 气道嗜酸粒细胞增多定义为支气管肺泡灌洗液中嗜酸粒细胞>1%总白细胞计数。
临床怎么用
- 对COPD患者可考虑通过BAL嗜酸粒细胞>1%识别可能从ICS治疗中获益的2型炎症亚群。
局限性
- 本研究为DISARM试验的事后分析,样本量有限(58例),需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A subset of COPD patients have high levels of eosinophils in the distal airways ("airway eosinophilia"). OBJECTIVES: To compare the gene expression of type 2 inflammation in airway epithelial brushings of COPD patients with and without airway eosinophilia and to investigate the changes after inhaled corticosteroids (ICS). METHODS: Post hoc analyses of the DISARM randomised controlled trial investigated the expression of airway inflammation (type 1, 2 and 17), interleukin (IL)-13 and mast cell gene signatures at baseline and after 12-week ICS treatment. Gene signatures were generated from RNA sequencing of airway epithelial brushings. Airway eosinophilia was defined as eosinophils >1% of the total leukocyte count in bronchoalveolar lavage. Gene set enrichment analyses identified upregulated canonical pathways in airway eosinophilia. RESULTS: Among 58 COPD patients, 38% had airway eosinophilia at baseline. Patients with airway eosinophilia had more severe airflow obstruction and more radiographic emphysema than the non-eosinophilia group. Patients with airway eosinophilia showed a higher epithelial expression of type 2 airway inflammation and IL-13 and mast cell activation at baseline, but the expression of type 1 and type 17 airway inflammation was similar to patients without airway eosinophilia. The airway eosinophilia group showed an upregulation of canonical pathways related to type 2 immune response and asthma. Treatment with ICS for 12 weeks reduced the epithelial expression of type 2 inflammation and mast cell gene signatures in patients with airway eosinophilia, while this change was not significant in patients without airway eosinophilia. CONCLUSIONS: Airway eosinophilia marks a subset of COPD patients with increased airway epithelial expression of type 2 inflammation and a response to ICS treatment.
引用
- Leung C, Park HY, Li X, et al. Transcriptomic profiling of the airway epithelium in COPD links airway eosinophilia to type 2 inflammation and corticosteroid response. Eur Respir J. 2025. PMID: 39978857. doi:10.1183/13993003.01875-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。